Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system

Objective: In recent years, the emergence of immunomodulatory drugs (IMiDs) has significantly improved clinical outcomes in patients with multiple myeloma (MM); however, serious adverse events (AEs) have hindered their safe clinical application. This study aimed to characterize the safety profiles a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Tingting, Su, Hui, Li, Yanping, Wu, Yuanlin, Ming, Yue, Li, Chen, Fu, Ruoqiu, Feng, Lu, Li, Ziwei, Li, Li, Ni, Rui, Liu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751748/
https://www.ncbi.nlm.nih.gov/pubmed/36532784
http://dx.doi.org/10.3389/fphar.2022.989032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751748/
https://www.ncbi.nlm.nih.gov/pubmed/36532784
http://dx.doi.org/10.3389/fphar.2022.989032

Ejemplares similares